Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: Results of the amlodipine diabetic hypertension efficacy response evaluation trial

Annals of Pharmacotherapy

Volumn 42, Issue 11, 2008, Pages 1552-1562

  Kloner, Robert A ^a,b,k   Neutel, Joel ^c   Roth, Eli M ^d   Weiss, Robert ^e   Weinberger, Myron H ^f   Thakker, Kamlesh M ^g   Schwartz, Brian ^h   Shi, Harry ⁱ   Gregg, Anne Marie ^j  

^a Section of International Research   (Puerto Rico)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Orange County Heart Institute and Research Center   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e Maine Research Associates   (United States)

^f INDIANA UNIVERSITY   (United States)

^g ABBOTT LABORATORIES   (United States)

^h Cardiovascular Therapeutics   (United States)

ⁱ PFIZER INC   (United States)

^j Acambis   (United States)

^k GOOD SAMARITAN HOSPITAL   (United States)

more..

Author keywords

Amlodipine besylate; Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Diabetes; Dihydropyridine calcium channel blocker; Hypertension; Losartan potassium; Quinapril HCL

Indexed keywords

AMLODIPINE; LOSARTAN; PLACEBO; QUINAPRIL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; LOSARTAN; MALE; MIDDLE AGED; TETRAHYDROISOQUINOLINES;

EID: 55949109604     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L076     Document Type: Article

References (39)

1. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001;37:1053-9.
2. Zanella MT, Kohlmann O Jr, Ribeiro AB. Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001;38:705-8.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
4. Vijan S, Hayward RA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 2003;138:593-602.
5. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-13.
6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62.
7. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999;340:677-84.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
9. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366:2026-33.
10. National Heart, Lung, and Blood Institute. ACCORD telebriefing prepared remarks. www.nhlbi.nih.gov/health/prof/heart/other/accord/index. htm (accessed 2008 Feb 6).
11. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003;289: 2560-72.
12. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31(suppl 1):S12-54.
13. Kidney Disease Outcomes Quality Initiative (K/DOQI), K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004;43:S1-290.
14. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in US academic medical centers: low rates of medical regimen change. Diabetes Care 2005;28:337-42.
15. Johnson ML, Pietz K, Battleman DS, Beyth RJ. Therapeutic goal attainment in patients with hypertension and dyslipidemia. Med Care 2006;44: 39-46.
16. Swislocki A, Noth RH, Volpp B, Meier J, Siegel D. Blood pressure control in a diabetic population assessed by computer review. J Hum Hypertens 2006;20:540-2.
17. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
18. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31.
19. Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61.
20. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
21. Bisognano J, McLaughlin T, Roberts CS, et al. Incremental effectiveness of amlodipine besylate in the treatment of hypertension with single and multiple medication regimens. Am J Hypertens 2004;17:676-83.
22. Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:1401-9.
23. Esnault VL, Brown EA, Apetrei E, et al. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies; a 3-year, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 2008;30:482-98.
24. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Anti-hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:936-46.
25. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 2007;369:201-7.
26. Leinung MC. The role of calcium antagonists in the treatment of hypertension in patients with diabetes: a reappraisal based on recent evidence. The Endocrinologist 2006;16:349-57.
27. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-97.
28. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39:S1-266.
29. Goldberg A, Sweet C. Efficacy and safety of losartan. Can J Cardiol 1995;11(suppl F):27F-32F.
30. Olvera S, Alcocer L, Novoa G. Usefulness of low-dose, once-daily quinapril as monotherapy for patients with hypertension. Clin Ther 1996; 18:864-73.
31. Hendrix K, Tang S, Thakker K, Fox J, Egan B. Adding dihydropyridine calcium channel blocker lowers BP in diabetic hypertensives irrespective of baseline treatment and demographics. J Clin Hypertens 2006;8:A82 (P-183).
32. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens 2006;24:185-92.
33. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13: 418-26.
34. Neutel JM, Smith DH, Weber MA. Low dose combination therapy vs high dose monotherapy in the management of hypertension. J Clin Hypertens (Greenwich) 1999;1:79-86.
35. Tobe S, Kawecka-Jaszcz K, Zannad F, Vetrovec G, Patni R, Shi H. Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) Trial. J Clin Hypertens (Greenwich) 2007;9:120-7.
36. Malacco E, Omboni S. Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination is superior to that of single components (abstract). Eur Heart J 2005;26:401.
37. Neutel JM, Smith DH, Weber MA, Schofield L, Purkayastha D, Gatlin M. Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich) 2005;7:641-6; quiz 7-8.
38. Nathan S, Pepine CJ, Bakris GL. Calcium antagonists: effects on cardiorenal risk in hypertensive patients. Hypertension 2005;46:637-42.
39. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-9.